Skip to Main Content

Amid a boom in genetic testing that aims to predict a person’s response to medication, the Food and Drug Administration has been quietly pressuring a handful of companies to stop reporting results to patients about how their genes may interact with specific drugs.

The agency’s concern? That unsupported claims about gene-drug links could be dangerous, if they spur patients to start, stop, or switch medications in ways that aren’t appropriate.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!